CITE-seq analysis predicts response to CAR-T therapy and bispecifics in myeloma

So, how do you pick between CAR T-cell therapy and #bispecifics?Подробнее

How to best sequence bispecific antibodies and CAR-T therapy in multiple myelomaПодробнее

Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapyПодробнее

What to Expect with CAR T Cell Therapy and Bispecifics in Myeloma (2022) | Dr. Joshua RichterПодробнее

Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myelomaПодробнее

Predicting response to CAR-T therapy with multi-omic approachesПодробнее

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myelomaПодробнее

Q&A | How to sequence CAR T-cell therapy and bispecific antibodies in R/R MMПодробнее

What are the differences between CAR T-cell therapy and bispecific antibodies?Подробнее

How quickly can a patient see a response with CAR-T cell therapy? #myelomaПодробнее

Bispecific antibodies vs CAR T-cells for R/R multiple myelomaПодробнее

CAR T Cell Therapy & Bispecifics: Cutting Edge Treatment in Myeloma | Dr. Joseph MikhaelПодробнее

The value of bispecific T-cell engager therapies in myeloma & future considerations for these agentsПодробнее

How can we predict responses to CAR T-cell therapies, such as bb2121?Подробнее

Comparison of the safety & efficacy of CAR-T therapy vs bispecifics in R/R multiple myelomaПодробнее

Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myelomaПодробнее

Session highlights: clinical indications for CAR-T therapy in multiple myelomaПодробнее

How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myelomaПодробнее

The CAR T-cell strategy vs bispecific antibodiesПодробнее